Lasofoxifene, a selective estrogen receptor modulator (SERM), appears to reduce the risk of breast cancer among postmenopausal women with osteoporosis. These findings were recently reported in the Journal of the National Cancer Institute. As a SERM, the investigational drug lasofoxifene …
Source: Breast Cancer News